Two Years Follow-Up of Patients with Abnormal Uterine Bleeding after Insertion of the Levonorgestrel-Releasing Intrauterine System

• Published in: Gynecologic and obstetric investigation Vol. 83; no. 6; p. 569
• Main Authors: Cim, Numan, Soysal, Sunullah, Sayan, Sena, Yildizhan, Begum, Karaman, Erbil, Cetin, Orkun, Tolunay, Harun Egemen, Yildizhan, Recep
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2018
• Subjects: Adult; Contraceptive Agents, Female - administration & dosage; Contraceptive Agents, Female - adverse effects; Endometrium - pathology; Female; Follow-Up Studies; Humans; Intrauterine Devices, Medicated - adverse effects; Levonorgestrel - administration & dosage; Levonorgestrel - adverse effects; Menorrhagia - therapy; Menstruation - drug effects; Middle Aged; Prospective Studies; Treatment Outcome; Turkey; Turkey; Pulsatile index; Endometrial biopsy; Heavy menstrual bleeding; Uterine volume; LNG-IUS; Levonorgestrel
• ISSN: 1423-002X
• DOI: 10.1159/000480012

To evaluate the efficacy and safety of levonorgestrel-releasing intrauterine system (LNG-IUS) in the long-term treatment of heavy menstrual blood loss in women unrelated to intrauterine pathology. One hundred and six parous women aged 33-48 years with recurrent heavy menstrual bleeding (HMB) participated in this study. The women were followed up for 24 months and were assessed for intensity of bleeding both for pre- and post-insertion periods. An LNG-IUS was inserted in each patient within 7 days of the start of menstrual flow. The women were followed up at 1, 3, 6, 12, 18, and 24 months following the insertion of the intrauterine device. One hundred and two women completed the follow-up period and had a significant reduction in the amount of menstrual blood loss. The LNG-IUS was well tolerated by all women. Pre-treatment of the use of the LNG-IUS, endometrial biopsy patterns for irregular proliferative endometrium and for atypical simple hyperplasia were 34/106 (32.08%) and 61/106 (57.55%) respectively and after treatment no abnormal pathologic findings were determined (p < 0.001). Our findings indicate that the LNG-IUS is effective for significantly reducing the amount of menstrual blood loss in women with HMB.